In Part II of our discussion with DARA Biosciences (NASDAQ: DARA) CEO and Chief Medical Officer Dr. David Drutz, we look into key catalysts for the specialty pharmaceutical company. Dr. Drutz discusses the medical need for the oral-liquid tamoxifen, Soltamox, licensed to DARA by UK-based Rosemont Pharmaceuticals — as well as the market opportunity in developing oncology services.
Dr. Cynthia Haines, Health Information Guru: How Patients Can Combat a Broken Healthcare System
In this unprecedented age of technology and communication, many wonder why the healthcare industry has traditionally not been on the cutting edge.
